EU/3/16/1805:

Propranolol

Overview

On 12 December 2016, orphan designation (EU/3/16/1805) was granted by the European Commission to The Anticancer Fund, Belgium, for propranolol for the treatment of soft tissue sarcoma.

Key facts

Active substance
Propranolol
Intented use
Treatment of soft tissue sarcoma
Date of designation
12/12/2016
Orphan designation status
Positive
EU designation number
EU/3/16/1805

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

The Anticancer Fund
Boechoutlaan 221
1853-Strombeek-Bever
Belgium
Tel. +32 2 268 48 16
E-mail: info@anticancerfund.org

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

How useful was this page?

Add your rating